Forkhead box M1 transcription factor: a novel target for pulmonary arterial hypertension therapy

2019 ◽  
Vol 16 (2) ◽  
pp. 113-119
Author(s):  
Li Gu ◽  
Han-Min Liu
Keyword(s):  
Transcription Factor ◽  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Forkhead Box ◽  
Forkhead Box M1 ◽  
Hypertension Therapy ◽  
Pulmonary Arterial ◽  
Novel Target ◽  
Pulmonary Arterial Hypertension Therapy

Outcomes of pulmonary arterial hypertension therapy in Australia: is monotherapy adequate?

2017 ◽  
Vol 47 (10) ◽  
pp. 1124-1128
Author(s):  
Avalon Moonen ◽  
Roger Garsia ◽  
Peter Youssef ◽  
Paul Torzillo ◽  
Tamera Corte ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Hypertension Therapy ◽  
Pulmonary Arterial ◽  
Pulmonary Arterial Hypertension Therapy

Evaluating Operability in Adults with Congenital Heart Disease and the Role of Pretreatment with Targeted Pulmonary Arterial Hypertension Therapy

2007 ◽  
Vol 6 (3) ◽  
pp. 126-135
Author(s):  
Konstantinos Dimopoulos ◽  
Michael A. Gatzoulis
Keyword(s):  
Congenital Heart Disease ◽  
Heart Disease ◽  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Congenital Heart ◽  
Heart Defects ◽  
Severe Form ◽  
Hypertension Therapy ◽  
Pulmonary Arterial ◽  
Pulmonary Arterial Hypertension Therapy

Despite recent advances in cardiac surgery that have allowed repair of congenital heart defects at a very young age, pulmonary arterial hypertension (PAH) secondary to congenital heart disease (CHD) remains a major problem. In its most severe form, the Eisenmenger syndrome, PAH and its complications result in a significant increase in morbidity and mortality and also greatly affect the quality of life of patients.

Sign in / Sign up

Export Citation Format

Share Document